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MEETING REPORT
Cancer Research Campaign Review of Radiobiology Research*
A. Horwich
The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK.
This meeting was held in London in January 1992 under the
auspices of the Cancer Research Campaign in order to review
current research in radiobiology in the UK and to seek to
identify growth areas within this subject. The focus of the
meeting was on aspects of radiobiology relevant to cancer
therapy.
The significant themes and comments were as follows:
(1) Clinical role ofradiotherapy
The strategic importance of radiobiology relates to the major
role which radiotherapy continues to play in the management
of cancer in the UK. Figure 1 which is derived from the
textbook 'Cancer and its Management', (R. Souhami & J.
Tobias, 1986), identifies the frequency with which cancers
present at a localised stage and also indicates the target for
improved local treatment since about 40% of these tumours
recur after initial local therapy with radiotherapy and/or
surgery. The 60% cure rate of cancer by local therapy is
contrasted with the cure rate of approximately 5% in a
similar number of patients treated for metastatic cancers.
Thus modest improvements in local therapy can translate to
improved survival of a large number of patients.
A key question is the extent to which radiotherapy must be
improved to have an impact on survival and the answer to
this clearly depends upon existing response patterns and on
rates of metastasis. However, for a range of solid tumours
where radiotherapy has been curative as the sole treatment
modality, there is clinical evidence both from dose/control
studies and from salvage studies that a modest (10-20%)
increase in dose could translate both to improved local con-
trol and to increased survival. It was emphasised that
radiotherapy also has important roles as a component of
multi-modality therapy. In particular it frequently allows a
more conservative surgical approach as with breast conserva-
tion for early tumours. A major component of radiotherapy
resources in the UK is employed in palliative treatment for
example ofpainful bone metastases, haemorrhage, cord com-
pression, venous/lymphatic obstruction, etc. In principle,
these approaches have not required doses of radiotherapy
close to tolerance and it is not envisaged that palliative
radiotherapy requires an extensive biological research base.
Current figures in the UK suggest that radiotherapy is
employed in approximately half of the 200,000 new cancer
patients per annum, with curative intent in two thirds of the
cases. Radiotherapy may have a larger curative role in the
future because of increasing proportions of tumours diag-
nosed at early stages as a consequence of the identification of
genetic predisposition to cancers, definition of premalignant
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(2) Contributions ofradiobiology
The discussion was opened by Professor Jens Overgaard
presenting a European perspective on previous contributions
of radiobiology to radiotherapy. He indicated a profound
effect on current clinical practice in relationship to dose,
fractionation, target volume and combined modality therapy.
He focused particularly on the investigations of tumour
hypoxia as a cause of radiation resistance and emphasised
the results of a meta-analysis of trials using either hyperbaric
oxygen or nitro-imidazole sensitisers which had clearly dem-
onstrated a significant survival advantage when these agents
were added to radiotherapy. Current routine clinical practice
is not based on these approaches however because the extent
of improvement was too small to warrant the difficulties in
implementation. Progress has been made in the design of
hypoxic cell radiosensitisers and clinical evaluation of this
field continues.
(3) Tumour hypoxia
The discussion of tumour hypoxia continued with a pre-
sentation from Professor Denekamp of animal tumour
radiosensitisation with the combination of carbogen (oxygen
+ carbon dioxide) and nicotinamide. This combined ap-
proach aims to resolve the problems of chronic tumour
hypoxia and also ofacute hypoxia due to capillary closure. A
marked radiosensitisation has been seen in two animal
tumour models, providing the basis for further radio-
biological research in this area and the hope of early clinical
application. The benefits seen with carbogen and nicotin-
amide appeared to be even greater with fractionated than
with single-fraction radiotherapy, raising the question wheth-
er other mechanisms of radiosensitisation are contributing to
the effect. A further point was that it may be optimal to
combine it with other approaches to overcoming radiation
resistance such as accelerated radiotherapy. The animal work
had suggested that nicotinamide doses ranging from 100 mg
kg-' to 500mgkg-' had a sensitising effect and pharma-
cokinetic data in human volunteers has demonstrated that a
dose of 6 g of nicotinamide would allow a serum concentra-
tion equivalent to the animal dose of 100 mgkg-'. Phase I
and II clinical studies are beginning.
Professor Adams pointed out that the current widespread
interest in the use of bioreductive drugs as anticancer agents,
derived from radiobiological research in hypoxia. Bioreduc-
tive drugs are agents that are metabolically reduced in cells
to form active cytotoxic substances. A variety of cellular
reductases including the p450 cytochrome reductase, DT
diaphorase, xanthine oxidases, etc., would be involved,
depending upon the individual cell type. The initial stages of
such bioactivation are reversed by oxygen and thus the
cytotoxic effect of these drugs is greatly enhanced in hypoxic
cells. The current emphasis in research is on selected struc-
tures of heterocyclic mono- and di-N-oxides, various
quinonoid structures some of which are related to Mito-
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Figure 1 Pattern of cancer presentation in the UK.
mycin-C and bifunctional nitroheterocyclic drugs. Two com-
pounds will shortly enter phase I clinical trial including
SR4233 a benztriazene di-N-oxide and RB6145, a pro-drug
for an aziridinyl nitrimidazole.
In this context, tumour hypoxia was a method of tumour
targeting and it was envisaged that bioreductively activated
drugs would be employed in combination with other
cytotoxic drugs, with vasoactive agents to influence the
degree of tumour hypoxia, or as a complement to radio-
therapy.
(4) Molecular basis ofradiation cytotoxicity
This subject included the specific DNA lesions underlying
carcinogenesis and cytotoxicity, the molecular and genetic
basis of human tumour radiosensitivity and models for this
radiosensitivity including ataxia telangiectasia and the radia-
tion sensitive mutants of cultured cells.
(a) Damage Ionising radiation produces a wide range of
types of DNA damage including base damage, single strand
breaks, double strand breaks, DNA-DNA and DNA-protein
crosslinks, and other adducts. These lesions could occur in
combinations of varying complexity.
The majority of this damage is repaired and it is clear that
the more simple abnormalities do not correlate well with
either cell killing or mutations. The best correlation with
cytotoxicity has been the DNA double strand break but
research has been limited by the relative insensitivity of
methods to detect small numbers of these breaks and the
difficulty in distinguishing different types of double strand
breaks. There have been several contributions to this field
from biophysics research. Dr Goodhead described how
simulation of radiation tracks could provide information on
frequency of single and clustered ionisations. The conclusion
has been that those clustered lesions that occur within DNA
could cause complex breaks in sufficient numbers to account
for both lethal and mutagenic damage. Differences in cell
sensitivity may arise from different yields at a particular
radiation dose of more complex forms of damage or from
subtle shifts in the ability to repair damage of intermediate
complexity. Techniques for more sensitive assays of DNA
lesions included the use of end-labelling techniques coupled
with endonuclease treatments to reveal base damage and
quantitation of short fragments released from clustered
damage sites. DNA electrophoresis techniques have improved
and include 'Comet' assays and pulsed-field techniques. Well
defined test systems such as plasmid DNA have been useful
to allow assessment of functional recovery as well as strand-
break rejoining.
(b) Ataxia telangiectasia and repair genes The genetic basis
of radiosensitivity is being investigated in the context of
ataxia telangectasia, radiation sensitive mutants of cultured
rodent cells and also in human tumours. The status of clon-
ing and characterisation of the AT gene was discussed
initially in the light of reports from UCSF suggesting that
genomic DNA fragments have been isolated from a partially
corrected AT cell line. The fragments mapped to human
chromosome 1 lq but homologous c-DNA did not correct the
AT phenotype. In the UK, two groups are working towards
cloning this gene with distinct approaches. Malcolm Taylor's
group in Birmingham has mapped the gene to within two
centimorgans of a linked marker sequence using positional
cloning techniques. Dr Arrand at the Gray laboratory has
isolated correcting hamster DNA from a fused cell deriving
from AT and a CHO line. The fused derivative was corrected
partially for all AT defects. The epidemiologically determined
link between AT heterozygotes and malignancy was discussed
and research was proposed to determine the status of the AT
gene in the ICR collection of breast tumour biopsies. With
regard to other genes which may be involved in the repair of
ionising radiation damage, the gene for DNA ligase I, poly-
(ADP ribose)-polymerase and a human AP endonuclease
have already been cloned. Other relevant genes may be
isolated using the cloned radiosensitivity genes from yeast.
Also, it has been found that radiation induces several pro-
teins, some of which are implicated in responses such as
carcinogenesis. Work is in progress to determine whether
these proteins form a coherent biochemical pathway affecting
responses to radiation which might allow the possibility of
therapeutic modulation. With regard to mutation, progress200 A. HORWICH
has been made in understanding the molecular lesions
involved. There is considerable scope for research exploring
links between radiation repair deficiency, radiation respon-
siveness, mutation frequency and cancer proneness.
(c) Human tumour radiosensitivity There is a wide clini-
cally-observed range in sensitivity among human tumour
types and this range is accurately reflected in cell survival
experiments in vitro. Research on the molecular basis of
human tumour radiosensitivity has investigated the develop-
ment of radiation damage including both induction of DNA
lesions and their repair. Additionally, cells appear to differ in
their tolerance of genetic loss. Dr McMillan discussed
research on the relationship between patterns of DNA
damage and radiation cytotoxicity and also of the influence
of endogenous thiols on damage induction. Also, large
differences have been observed in the rate and extent of
disappearance of DNA damage which appear to be impor-
tant in determining the sensitivity of some cell lines. Even
where strand breaks are rejoined, it has been demonstrated
that a functional deficit can remain. Repair fidelity has been
investigated using plasmids containing defined endonuclease-
induced breaks.
The number of critical target genes for radiation induced
cytotoxicity is unknown but the tolerance of chromosome
fragment loss has been found to differ amongst human
tumour cells and this may relate to ploidy or DNA methyla-
tion status. In summary, it was felt that molecular techniques
should continue to be employed to characterise the basis of
human tumour cell radiosensitivity and this field of research
may in the long term lead to new ways of selectively modify-
ing radiation effect. In the shorter term would be likely to
provide biochemical tests for radiosensitivity of both normal
tissues and tumours. This information could be important in
tailoring clinical radiotherapy for individual patients.
(5) Normal tissue damage
It was recognised that in clinical radiotherapy the dose and
thus antitumour effect is limited usually by the late normal
tissue toxicity and Dr Hopewell presented several possible
approaches to maximise the therapeutic ratio with radiation.
One novel approach providing the current focus for this field
was the use of biological response modifiers, especially those
developed for use in other vascular-mediated disease. Ap-
proaches included the use of haemorheological agents to
correct for impairments in microcirculation and free-radical
scavengers to prevent reperfusion injury. A distinct approach
to preventing the development of radiation-induced vascular
damage would be to correct for the radiation-induced
imbalance in eicosanoid metabolism. Anti-adhesion mole-
cules may also be useful in this context. He presented
preliminary research showing that radiation damage could be
modified using these principles, and indicated that response
modifiers were effective when given for the period after
irradiation when the tissue was at particular risk. Specific
modification factors of 1.2-1.4 could be achieved, i.e., dose
escalation of 20% or more could be evaluated.
(6) Alteredfractionation
An alternative approach to reducing late radiation reactions
presented by Dr Joiner, has been to reduce the dose per
fraction below 2 Gy (hyperfractionation). In principle, this
allows the total radiation dose to be raised while maintaining
the same late tissue tolerance and this would be predicted to
have a greater antitumour effect. This concept, which derived
from laboratory radiobiology, has been tested in phase III
trial (EORTC trial 22791). This study of the treatment of
head and neck cancers compared 70 fractions of 1.15 Gy
( x 2 per day) to a total dose of 80.5 Gy with a conventional
schedule of 35 fractions of 2 Gy to a total dose of 70 Gy.
The overall treatment time for both schedules was 7 weeks.
The trial demonstrated a substantial increase in local tumour
control with no significant difference in late tissue damage.
Current research seeks to establish how widely this principle
of hyperfractionation may be applied. There are resource
implications in reducing the fraction size since more
radiotherapy treatments need to be given to each patient.
There is evidence that the protective effect of hyperfractiona-
tion is different for different tissues and therefore the ideal
fraction size at different sites needs to be established
independently for each site. Since the clinical consequence of
radiation overdose in patients is catastrophic and occurs long
after treatment has been completed, there is an important
requirement for laboratory models in this field. Another
parameter requiring optimisation is the interfraction interval
which is determined by the rate of repair of radiation damage
within the target tissue.-A coherent model of response thus
requires research on fraction size, interfraction interval, indi-
vidual tissue, dose rate and also the volume effect.
Another contribution of radiation research to the field of
tumour biology in general has been the focus on cell kinetics.
Of particular importance to radiotherapy has been the
demonstration that tumours are capable of rapid prolifera-
tion during treatment. Dr Wilson described how the potential
doubling time of tumour clonogens can be estimated using
flow cytometric techniques after bromodeoxuridine labelling
and these studies have provided the basis for justifying the
intensification of radiotherapy using the technique of
accelerated fractionation. In this technique, treatment is
given using more than one fraction per day maintaining a
conventional fraction size in order to preserve normal-tissue
tolerance. A variety of accelerated radiotherapy schedules are
under investigation. In order to achieve treatment
intensification, these have required either the acceptance of
increased acute radiation reactions or a reduction in the
radiotherapy dose, or both. Laboratory models and clinical
trials have demonstrated the effectiveness of accelerated
radiotherapy in rapidly growing tumours. However, the
associated dose compromise make it important to define
whether in the individual patient accelerated approach is
appropriate. It is therefore important to continue to develop
rapid predictive assessments of tumour proliferation, as well
as models of normal tissue tolerance.
In the UK, a particularly intensive approach to accelerated
radiotherapy has been explored, the CHART regimen (Con-
tinuous Hyperfractionated Accelerated Radiation Therapy).
The entire radiation dose is given within 12 days. This ap-
proach was pioneered at the Mount Vernon Hospital by
Professor Dische and Dr Saunders. Pilot studies in non small
cell carcinoma of the bronchus and in advanced head and
neck cancers based on discussion with the CRC Gray
Laboratory radiobiologists, showed an improvement com-
pared with historical controls. The CHART regimen is cur-
rently being investigated in prospective randomised national
trials coordinated by the Medical Research Council and such
is the level of interest in these treatments that within the first
2 years of these trials, 625 patients had been entered.
(7) Predictive testing
The field of predictive testing is particularly appropriate to
radiotherapy and contains three main components:
(i) assessment of tumour and normal tissue radiosen-
sitivity
(ii) assessment of tumour proliferation capacity
(iii) assessment of hypoxia.
It has been demonstrated that there is a correlation between
the average radiosensitivity of tumour cell lines assessed by
laboratory cell survival studies and the clinical response to
these tumour types. However, even within tumour types,
radiotherapy response is heterogeneous and there is a clear
clinical need to establish in individual patients the radio-
sensitivity of both tumour and normal tissue. A number of
centres have shown that tumours that respond poorly to
radiotherapy can be shown in laboratory tests to be more
resistant than tumours responding well. Dr West reported
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differences in recurrence-free survival which correlated well
with results of clonogenic assay radiosensitivity using
primary cultures. With regard to normal tissues, a number of
studies have been published indicating that skin fibroblasts
cultured from patients suffering severe radiation reactions
showed enhanced cellular radiosensitivity. A problem with
these clonogenic assays is the time required to determine
sensitivity since it would not always be acceptable to delay a
treatment decision radiotherapy for more than 2-3 weeks
while analysing radiosensitivity in the laboratory. Alternative
measures of sensitivity such as nucleoid light scatter or mic-
ronucleus induction are under investigation. There is a need
for prospective comparison ofpredictive laboratory tests with
clinical outcome, for the demonstration that response to the
information deriving from predictive tests can improve treat-
ment results, and for the evaluation of multiple complemen-
tary tests on the same tumour providing information relating
to different parameters of treatment.
There is a strong clinical support for this area of
radiobiology and it was emphasised that reduction of radia-
tion toxicity was an important goal. The research would
provide information on the relationship between normal-
tissue radiosensitivity and human tumour radiosensitivity in
the same individual. It was estimated by Dr Hunter that for
bladder or cervix cancers, accurate predictive testing might
allow a 5-10% increase in tumour control and it was noted
that an estimate of this parameter from the M D Anderson
hospital was 20%.
(8) Targeted radiotherapy
Dr Wheldon and Professor Barratt presented the concept and
experience of targeted radionuclide therapy. Targeting could
be achieved by antibodies, metabolic precursors (e.g. MIBG
in neuroblastoma), growth factors or possibly oligo-
nucleotides. Research is being carried out based on iodine-
131 or yttrium-90 but there is considerable potential for
experimental work based on astatine-211 and bismuth-212. It
was envisaged that for gene targeting Auger emitters may be
the radionuclides of choice because of their short range and
high biological effectiveness. A unique feature of targeted
therapy is the relationship between tumour size and radiation
dose delivered with the target volume leading paradoxically
to situations in which larger tumours may be treated more
successfully than smaller ones. A second problem is
heterogeneity of the tumours for the targeting technique
leading to non-uniform dose for short-range isotopes. A third
variable might be the combination of targeted therapy with
external beam radiotherapy since mathematical modelling
consistently predicts a therapeutic advantage for that
strategy; thus a preliminary study of 1-131 MIBG therapy in
conjunction with total body irradiation and bone-marrow
rescue is being undertaken in Glasgow. The argument was
presented that targeted isotopes may be more effective than
targeted cytotoxic drugs in that only 103 atoms of Iodine 125
targeted to DNA were necessary to produce 1 log of cell kill
compared with 107 to 108 molecules of daunomycin reaching
the nucleus.
(9) Summary
The meeting was reviewed and summarised by Professor
Herman Suit. Hejudged that the potential clinical gains from
research in radiobiology were very great and likely to trans-
late to improved cancer treatment in the near future. He was
highly complimentary about the contribution of UK research
in radiobiology and he indicated that this viewpoint was held
widely in the United States, Europe and Japan. Radio-
biological research was the basis for major clinical trials in
radiotherapy undertaken by trial groups in all these coun-
tries. He felt that major contributions to current practice in
radiotherapy had been the definition of dose response, the
rationale for the use of radiotherapy against slowly respond-
ing tumours, and the understanding of repair differentials
and of clonal proliferation in the design of clinical fractiona-
tion trials, leading to clear demonstration of benefit for
altered fractionation in the treatment of head and neck
cancer and in the treatment of bladder cancer.
An important goal of research should be the development
of predictive testing for radiation response employing multi-
ple predictive tests of radiation sensitivity (survival at 2 Gy),
cellular proliferation (potential doubling time) and
identification of hypoxic cells, together with physiological
parameters such as blood flow intratumoral pressure, thiol
metabolism and activation and status of repair genes. In
terms of improving differential response between tumour and
normal tissues, further refinement of dose fractionation pat-
terns would be needed, but also research should continue on
the modification of response using drug/radiation protocols,
targeting techniques, growth factors and other biological re-
sponse modifiers to support normal tissues, and modulation
of DNA repair.
Professor Suit felt that the pace of research in radiobiology
was most encouraging for the field of radiotherapy. There
was a consensus that support for radiobiology needed to be
matched by support for academic radiotherapy if potential
research gains were to be translated into advances in treat-
ment. He shared the view expressed by the Committee of
Cancer Experts of the EORTC that improvements in cancer
cure over the next decade were likely to derive from im-
provements in radiotherapy.